RBC Capital Upgrades Regenxbio to Outperform, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi upgraded Regenxbio (NASDAQ:RGNX) from Sector Perform to Outperform and increased the price target from $20 to $35.
March 08, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio was upgraded by RBC Capital from Sector Perform to Outperform with a price target increase from $20 to $35.
Upgrades by reputable analysts like RBC Capital typically lead to positive short-term price movements. The significant increase in the price target from $20 to $35 suggests a strong conviction in the company's future performance, likely influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100